| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H30F2N2O4 |
| Molecular Weight | 460.5135 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C2=CC=C(O)C3=C2C=CC(=O)N3
InChI
InChIKey=SFYAXIFVXBKRPK-QFIPXVFZSA-N
InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
| Molecular Formula | C25H30F2N2O4 |
| Molecular Weight | 460.5135 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Abediterol, a fast and long-acting β2-adrenoceptor agonist (LABA), is being developed by AstraZeneca, for the treatment of asthma and chronic obstructive pulmonary disease. The investigational drug is a long-acting beta2-agonist (LABA) that has a bronchodilator effect, relaxing the muscles around the airways. It is currently under development and is in Phase II clinical trials.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
The first Phase 2 study of abediterol as a COPD treatment was completed in 2012. It evaluate four single doses of inhaled abediterol at 0.625, 2.5, 5 or 10 ug. Results showed that all doses significantly improved bronchodilation when compared to a placebo. Doses of 2.5, 5, and 10 ug also showed improvements when compared to the active comparator.
Route of Administration:
Respiratory
